Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 28 clinical trials
Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

the venous sinus may improve patients' objective symptoms (such as visual loss and papilledema) and subjective symptoms (such as headache). This study will determine whether dural venous sinus

  • 29 Sep, 2021
  • 2 locations
Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities

conditions but also in virtual reality (VR). This tool can be used to measure a therapeutic benefit for new treatments (like gene therapy, retinal implants, intra vitreous injections ) for visual loss

other disease
retinal degeneration
gene therapy
  • 24 Jan, 2021
  • 1 location
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (TELeMAC)

manifestations of Coats' disease. It can be complicated by macular edema due to leakage from microvascular ectasia. When associated with visual loss, macular edema can be treated with different strategies

  • 15 Feb, 2022
  • 1 location
Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD) that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a widely-used, effective anti-vascular endothelial growth factor treatment regimen for neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to investigate the 18-month …

  • 04 Oct, 2022
  • 1 location
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) (ReCOVER)

The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior …

  • 07 Oct, 2022
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter …

tumor necrosis factor
  • 14 Jul, 2022
  • 19 locations
Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage

be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.

Accepts healthy volunteers
visual loss
  • 05 Nov, 2021
  • 1 location
Investigation of Potential Retinal Toxicity Associated With Hair Dye Products Containing pPD Type Aromatic Amines (CAPITOX)

are likely to be underdiagnosed, since the associated visual loss is usually mild and so this condition should be considered when patients report blurred vision. The aim of the study is to analyze

Accepts healthy volunteers
  • 25 Mar, 2022
  • 1 location
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR

development PDR within 1 year follow up, 45% will develop high-risk PDR, nearly half of PDR will experience profound visual loss. panretinal photocoagulation (PRP) only reduced 50% risk of sever visual loss

  • 23 Feb, 2022
  • 1 location
Optic Neuritis Differential Diagnosis Study (ONDDS)

used in NMO are different from those used in MS, which can worsen the natural history of NMO. Early differential diagnosis of these diseases is thus crucial for preventing severe visual loss and

optical coherence tomography
visual loss
demyelinating disorder
optic neuritis
  • 10 Mar, 2022
  • 1 location